Abivax (AAVXF) Invested Capital (2021 - 2025)

Abivax has reported Invested Capital over the past 5 years, most recently at $37.4 million for Q4 2025.

  • Quarterly results put Invested Capital at $37.4 million for Q4 2025, down 69.33% from a year ago — trailing twelve months through Dec 2025 was $292.9 million (down 10.15% YoY), and the annual figure for FY2025 was $36.3 million, down 70.61%.
  • Invested Capital for Q4 2025 was $37.4 million at Abivax, down from $121.8 million in the prior quarter.
  • Over the last five years, Invested Capital for AAVXF hit a ceiling of $121.8 million in Q4 2024 and a floor of $37.4 million in Q4 2025.
  • Median Invested Capital over the past 5 years was $70.5 million (2021), compared with a mean of $72.7 million.
  • Biggest five-year swings in Invested Capital: surged 63.16% in 2023 and later crashed 69.33% in 2025.
  • Abivax's Invested Capital stood at $70.5 million in 2021, then decreased by 27.89% to $50.8 million in 2022, then surged by 63.16% to $82.9 million in 2023, then skyrocketed by 46.96% to $121.8 million in 2024, then crashed by 69.33% to $37.4 million in 2025.
  • The last three reported values for Invested Capital were $37.4 million (Q4 2025), $121.8 million (Q4 2024), and $82.9 million (Q4 2023) per Business Quant data.